Publication: 2562

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001
      QxMD      Google Scholar   
Citation:
Blood Adv vol 1 (5) 331-340
Year:
2017
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
Received
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
6
Parents:
2036   2372   2379  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
Bayer  
Grants:
U10CA180821, U10CA180882, U10CA180802, U10CA180836, U10CA180850, U10CA180867, K23CA140707, P50CA100632, CA31946, CA33601, U10CA031983, U10CA032291, U10CA033601, U10CA003927, U10CA041287, U10CA077440, U10 CA032291, U10 CA052784, U10 CA077658, K23 CA140707, P50 CA100632, U10 CA035279, U10 CA045808, U10 CA007968, UG1 CA189869, U10 CA033601, U10 CA180854, U10 CA180821, U10 CA045418, U10 CA180836, UG1 CA189858, U10 CA077440, U10 CA180850, UG1 CA189850, U10 CA041287, U10 CA180882, UG1 CA189819, U10 CA180833, U10 CA180867, U10 CA003927  
Corr. Author:
 
Authors:
                                   
Networks:
CA043, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY158, LAPS-OH007, MAINE, MD015, NC002   
Study
CALGB-11001
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Article